Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm

Educational Webinar hosted by POINT Biopharma
Thursday, August 18, 2022 at 12:00 PM ET


On Thursday, August 18, 2022 at 12:00 PM ET, POINT Biopharma hosted a 45-minute educational webinar entitled “Understanding the PNT2002 SPLASH Trial Control Arm”.

The webinar featured presentations from two key opinion leaders: Dr. Oliver Sartor & Dr. Kim Chi. They were joined by members of the Company’s executive leadership team including Dr. Sherin Al-Safadi, VP Medical Affairs.


Presentation Topics:

  • Overview of SPLASH trial design (including lead-in phase) and rationale for hormone switches
  • What is a control arm benchmark, why PROfound1 & IMbassador2502 were selected as SPLASH benchmarks
  • Review current treatment patterns, including sequencing considerations, in real-world clinical settings for mCRPC patients

  1. De Bono et al. N Engl J Med 2020; 382:2091-2102.
  2. Powles T, et al. Nature Med 2022; 28:144-153.

Download the slides from this presentation: 

Event Speakers:


Oliver Sartor, M.D., Ph.D.

Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three radiopharmaceutical phase III studies pivotal for FDA approval in prostate cancer (Samarium-153 EDTMP, Radium-223, and Lu-177-PSMA-617). He has lectured widely, and at last count has given invited lectures in 33 countries.

He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments. He is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Head Shot

Kim Chi, M.D.

Kim Chi is a medical oncologist and the Chief Medical Officer of BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia (BC), in Canada. He is also Professor of Medicine at the University of British Columbia, in Vancouver, BC.

Prof. Chi's research in the field of genitourinary cancers focuses on prostate cancer and investigational new drugs, where he has contributed to changing international standards of care practice for patients with advanced prostate cancer. Recently, he has been investigating circulating tumour DNA as a potential prognostic and predictive biomarker for patients with castration-resistant prostate cancer. Prof. Chi is the past-Chair of the Genitourinary Disease Site Committee for the Canadian Cancer Trials Group, and has held peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defence, Movember, Prostate Cancer Foundation (USA), and Prostate Cancer Canada.

Prof. Chi has published widely in prestigious peer-reviewed journals including most recently the Journal of Clinical Oncology, Annals of Oncology, Nature, the New England Journal of Medicine, and Lancet Oncology.

Speakers from POINT Biopharma

Sherin (color) (1) crop

Sherin Al-Safadi, Ph.D., MBA

Sherin is responsible for medical affairs at POINT. Previously, she was the Global Medical Affairs Oncology Strategy Director at Bayer, where she developed and executed the medical strategy for the prostate cancer franchise, including the radiopharmaceutical Xofigo®. Dr. Al-Safadi graduated with an MSc in Pharmacology and Therapeutics from McGill University and earned her PhD in Neurobiology from Concordia University following her MBA in Entrepreneurship and Management at the John Molson School of Business.